News

Alopecia areata is an autoimmune disease characterized by patchy or widespread hair loss, for which there is significant unmet medical need and currently no FDA-approved treatment. CTP-543 is

The study, dubbed Resorce, enrolled 573 subjects who were randomized 2:1 to receive either regorafenib plus best supportive care (BSC) or placebo plus BSC. Patients were treated with

Based at BioCity, Nottingham, UK, Haemostatix is developing a pipeline of topical products for surgical bleeding. The company has developed a platform that utilizes synthetic peptide-based haemostats to

The company’s biologics license application included results from a pivotal phase 2 open-label, randomized trial that assessed the addition of olaratumab to doxorubicin chemotherapy in patients with advanced

The study, termed EMPIRE-CF (Evaluating Modulation of the Pulmonary Inflammatory Response in CF), will include approximately 30 sites across the EU, with sites in the United Kingdom, France,

The Study, which is a Phase IIa trial, will be conducted under the leadership of principal investigator, Andrea Branch, PhD, Professor of Medicine in the Icahn School of

KYNAMRO is approved in the United States for use in patients with homozygous familial hypercholesterolemia (HoFH) to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apoB), total cholesterol (TC)

This is the first company sponsored clinical trial evaluating the safety, tolerability, and efficacy of TG-1101 in autoimmune diseases. The Company is also supporting an investigator-sponsored study at

Papulopustular rosacea is a chronic skin disorder characterized by facial redness and inflammatory lesions. It affects more than 16 million people in the U.S. alone. The most common